Kura Oncology (NASDAQ:KURA) posted its earnings results on Tuesday, May 7th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.08, Morningstar.com reports.
Shares of NASDAQ:KURA traded up $0.26 on Friday, reaching $16.24. 703 shares of the company traded hands, compared to its average volume of 183,745. The company has a market capitalization of $619.82 million, a PE ratio of -9.44 and a beta of 2.79. Kura Oncology has a fifty-two week low of $10.20 and a fifty-two week high of $22.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.80 and a current ratio of 13.80.
A number of equities analysts recently issued reports on KURA shares. ValuEngine lowered Kura Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, February 13th. Oppenheimer restated a “buy” rating on shares of Kura Oncology in a research report on Tuesday, March 19th. BidaskClub downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Wednesday, May 8th. Finally, HC Wainwright set a $31.00 target price on Kura Oncology and gave the stock a “buy” rating in a research report on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $27.83.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Rockland Register and is owned by of Rockland Register. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://rocklandregister.com/2019/05/31/kura-oncology-kura-releases-earnings-results-beats-estimates-by-0-08-eps.html.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Story: What is a resistance level?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.